← All trials
NCT04847232
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 30, 2021
- Primary completion
- Mar 22, 2024
- Completion date
- Mar 22, 2024
- First posted
- Apr 19, 2021
- Last posted
- Nov 22, 2021
- Enrollment
- 2300
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- AstraZenecaLead sponsor
- North Shore University HospitalOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.